Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Exxon Mobil Corporation — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Exxon Mobil Corporation trades at $159.39 (market cap $634.34B). The key difference: Exxon Mobil Corporation is far larger — about 67.6× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Exxon Mobil Corporation pays a 2.69% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | XOM | |
|---|---|---|
Market Cap | $9.39B | $634.34B |
Sector | Health | Energy |
52-Week High | $356.25 | $171.52 |
52-Week Low | $241.71 | $106.13 |
Enterprise Value | $9.14B | $673.57B |
Dividend Yield | — | 2.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
ExxonMobil (XOM) trades at $159.80, up 4.49% today, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed results, beating in Q1 2026 but missing in Q2, while revenue and net income have trended lower since 2022. The company maintains robust cash flow from operations and a solid balance sheet with low debt levels, supporting consistent dividends.
Outlook remains positive due to high oil price forecasts and Permian Basin growth, but risks include declining profitability margins and geopolitical volatility. The stock offers value near the consensus price target of $163.71, with institutional sentiment leaning bullish amid energy sector tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
